Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence

In this video, David A. Ginsberg, MD, discusses the takeaways of the study, “Long-term, repeat treatments with onabotulinumtoxinA are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.